{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:18:50Z","timestamp":1786119530625,"version":"build-2736575974"},"reference-count":33,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"C","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,28]],"date-time":"2025-06-28T00:00:00Z","timestamp":1751068800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,8]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Secondary Sj\u00f6gren's syndrome (sSD) is a typical oral manifestation of systemic lupus erythematosus (SLE), which manifests itself in the form of xerostomia and mucositis and often makes dental treatment more complex. Anifrolumab, a type I interferon receptor antagonist (IFNAR1), was recently approved for the treatment of moderate-to-severe SLE. However, its potential benefit in sSD-particularly in addressing oral disease burden-remains unreported.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation:<\/jats:title>\n                    <jats:p>We describe a 40-year-old woman diagnosed with SLE, secondary Sj\u00f6gren's syndrome, rheumatoid arthritis, and osteopenia, who presented with persistent xerostomia, mucosal inflammation, joint pain, and cutaneous lupus despite long-term immunosuppressive therapy. Anifrolumab (300 mg IV every 28 days) was initiated in November 2022. Over the subsequent six months, the patient experienced marked improvement in cutaneous and systemic symptoms, alongside enhanced salivary flow and reduced oral inflammation. The resolution of xerostomia facilitated successful dental rehabilitation, including sinus floor augmentation, socket preservation and dental implant-supported prosthetics.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion:<\/jats:title>\n                    <jats:p>This case illustrates the broader therapeutic potential of interferon blockade in autoimmune diseases with mucosal involvement. By targeting IFNAR1, anifrolumab may interrupt the pathogenic loop of type I interferon-driven inflammation and B-cell dysregulation, resulting in both systemic and oral clinical improvement.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Anifrolumab may offer meaningful benefit for patients with secondary Sj\u00f6gren's syndrome beyond conventional SLE control, particularly in improving oral health outcomes. Further clinical studies are warranted to evaluate its efficacy in mucosal autoimmune manifestations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Graphical abstract:<\/jats:title>\n                    <jats:p>JOURNAL\/ijscr\/04.03\/01612930-202508000-00091\/figure1\/v\/2026-03-09T120122Z\/r\/image-jpeg<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Highlights<\/jats:title>\n                  <\/jats:sec>","DOI":"10.1016\/j.ijscr.2025.111593","type":"journal-article","created":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T03:42:49Z","timestamp":1751427769000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Marked improvement of oral manifestations in systemic lupus erythematosus after therapy with IFNAR1 blocking antibody (anifrolumab): A case report"],"prefix":"10.1097","volume":"133","author":[{"given":"Tim","family":"Schiepek","sequence":"first","affiliation":[{"name":"Center for Oral and Maxillofacial Surgery, Department of Dentistry, Faculty of Medicine and Dentistry, Danube Private University, Steiner Landstra\u0432e 124, 3500 Krems, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal","family":"Gr\u00fcn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flora","family":"Turhani","sequence":"additional","affiliation":[{"name":"Center for Oral and Maxillofacial Surgery, Department of Dentistry, Faculty of Medicine and Dentistry, Danube Private University, Steiner Landstra\u0432e 124, 3500 Krems, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann-Sophie","family":"Gr\u00fcn","sequence":"additional","affiliation":[{"name":"Center for Oral and Maxillofacial Surgery, Department of Dentistry, Faculty of Medicine and Dentistry, Danube Private University, Steiner Landstra\u0432e 124, 3500 Krems, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Holzhauer","sequence":"additional","affiliation":[{"name":"Faculty of Medicine and Dentistry, Danube Private University, Steiner Landstrasse 124, 3500 Krems, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dritan","family":"Turhani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-91-20260310","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1007\/s40265-021-01604-z","article-title":"Anifrolumab: first approval","volume":"81","author":"Deeks","year":"2021","journal-title":"Drugs"},{"key":"R2-91-20260310","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1182\/blood.V83.2.435.435","article-title":"Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20","volume":"83","author":"Reff","year":"1994","journal-title":"Blood"},{"key":"R3-91-20260310","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1002\/art.42392","article-title":"A randomized, placebo-controlled phase III extension trial of the long-term safety and tolerability of anifrolumab in active systemic lupus erythematosus","volume":"75","author":"Kalunian","year":"2023","journal-title":"Arthritis Rheum"},{"key":"R4-91-20260310","doi-asserted-by":"crossref","first-page":"ITC81","DOI":"10.7326\/AITC202006020","article-title":"Systemic lupus erythematosus","volume":"172","author":"Kiriakidou","year":"2020","journal-title":"Ann. Intern. Med"},{"key":"R5-91-20260310","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1136\/ard-2022-223035","article-title":"Global epidemiology of systemic lupus erythematosus: a comprehensive systematic analysis and modelling study","volume":"82","author":"Tian","year":"2023","journal-title":"Ann. Rheum. Dis"},{"key":"R6-91-20260310","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1093\/rheumatology\/kex260","article-title":"The worldwide incidence and prevalence of systemic lupus erythematosus: a systematic review of epidemiological studies","volume":"56","author":"Rees","year":"2017","journal-title":"Rheumatology"},{"key":"R7-91-20260310","first-page":"34","article-title":"Versuch einer auf pathologische Anatomie gegr\u00fcndeten Eintheilung der Hautkrankheiten","volume":"2","author":"von Hebra","year":"1845","journal-title":"Gesellschaft \u00c4rzte Wien"},{"issue":"9-10","key":"R8-91-20260310","doi-asserted-by":"crossref","first-page":"567","DOI":"10.2298\/SARH170912209T","article-title":"Oral rehabilitation of a patient with systemic lupus erythematosus using implant-supported fixed dentures: a case report with review of important considerations","volume":"146","author":"Todorovic","year":"2018","journal-title":"Srp. Arh. Celok. Lek"},{"issue":"3","key":"R9-91-20260310","doi-asserted-by":"crossref","DOI":"10.1111\/sji.13145","article-title":"Disease mechanisms in Sj\u00f6gren's syndrome: what do we know?","volume":"95","author":"Jonsson","year":"2022","journal-title":"Scand. J. Immunol"},{"key":"R10-91-20260310","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1016\/j.arcmed.2006.08.002","article-title":"Pathophysiology of Sj\u00f6gren's syndrome","volume":"37","author":"Garc\u00eda-Carrasco","year":"2006","journal-title":"Arch. Med. Res"},{"issue":"1","key":"R11-91-20260310","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s10238-021-00728-6","article-title":"Sj\u00f6gren's syndrome: a systemic autoimmune disease","volume":"22","author":"Negrini","year":"2022","journal-title":"Clin. Exp. Med"},{"key":"R12-91-20260310","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0289335","article-title":"Characterizing clinical findings of Sj\u00f6gren's disease patients in community practices using matched electronic dental-health record data","volume":"18","author":"Felix Gomez","year":"2023","journal-title":"PLoSOne"},{"key":"R13-91-20260310","doi-asserted-by":"crossref","first-page":"174","DOI":"10.3390\/jfb14040174","article-title":"Full-mouth rehabilitation of a patient with Sjogren's syndrome with maxillary titanium-zirconia and mandibular monolithic zirconia implant prostheses fabricated with CAD\/CAM technology: a clinical report","volume":"14","author":"Azpiazu-Flores","year":"2023","journal-title":"J Funct Biomater"},{"key":"R14-91-20260310","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1016\/S0031-3955(16)40060-X","article-title":"A practical guide to systemic lupus erythematosus","volume":"42","author":"Lehman","year":"1995","journal-title":"Pediatr. Clin. N. Am"},{"key":"R15-91-20260310","doi-asserted-by":"crossref","first-page":"7821","DOI":"10.3390\/ijms22157821","article-title":"An overview of physical, microbiological and immune barriers of oral mucosa","volume":"22","author":"\u015eenel","year":"2021","journal-title":"Int. J. Mol. Sci"},{"issue":"354","key":"R16-91-20260310","first-page":"61","article-title":"The diagnosis and treatment of Sj\u00f6gren's syndrome","volume":"114","author":"Stefanski","year":"2017","journal-title":"Dtsch. Arztebl. Int"},{"key":"R17-91-20260310","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2021.102615","article-title":"Clinical disease activity and flare in SLE: current concepts and novel biomarkers","volume":"119","author":"Thanou","year":"2021","journal-title":"J. Autoimmun"},{"key":"R18-91-20260310","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1093\/mr\/roac140","article-title":"Interferons and systemic lupus erythematosus: pathogenesis, clinical features, and treatments in interferon-driven disease","volume":"33","author":"Tanaka","year":"2023","journal-title":"Mod. Rheumatol"},{"key":"R19-91-20260310","doi-asserted-by":"crossref","first-page":"963","DOI":"10.3390\/cells8090963","article-title":"Signaling pathways of type I and type III interferons and targeted therapies in systemic lupus erythematosus","volume":"8","author":"Chyuan","year":"2019","journal-title":"Cells"},{"issue":"4","key":"R20-91-20260310","first-page":"21","article-title":"The importance of the type I interferon system in autoimmunity","volume":"34","author":"R\u00f6nnblom","year":"2016","journal-title":"Clin. Exp. Rheumatol"},{"key":"R21-91-20260310","doi-asserted-by":"crossref","first-page":"196","DOI":"10.3109\/08916930903510872","article-title":"Type I interferons in systemic autoimmunity","volume":"43","author":"Sozzani","year":"2010","journal-title":"Autoimmunity"},{"key":"R22-91-20260310","doi-asserted-by":"crossref","first-page":"299","DOI":"10.3389\/fimmu.2018.00299","article-title":"Interferon-\u03b1 subtypes as an adjunct therapeutic approach for human immunodeficiency virus functional cure","volume":"9","author":"George","year":"2018","journal-title":"Front. Immunol"},{"issue":"3","key":"R23-91-20260310","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1136\/annrheumdis-2013-203991","article-title":"Efficacy and safety of belimumab in primary Sj\u00f6gren's syndrome: results of the BELISS open-label phase II study","volume":"74","author":"Mariette","year":"2015","journal-title":"Ann. Rheum. Dis"},{"issue":"1","key":"R24-91-20260310","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1186\/s12903-024-04224-7","article-title":"Oral health status, related behaviours and perceived stress in xerostomia, Sicca and Sj\u00f6gren's syndromes patients - a cross-sectional study","volume":"24","author":"Stankeviciene","year":"2024","journal-title":"BMC Oral Health"},{"issue":"3","key":"R25-91-20260310","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.prosdent.2021.05.009","article-title":"Novel impacts of saliva with regard to oral health","volume":"127","author":"Uchida","year":"2022","journal-title":"J. Prosthet. Dent"},{"issue":"1","key":"R26-91-20260310","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1038\/s41368-022-00163-7","article-title":"Oral microbiota in human systematic diseases","volume":"14","author":"Peng","year":"2022","journal-title":"Int J Oral Sci"},{"issue":"2","key":"R27-91-20260310","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/s41579-023-00963-6","article-title":"The oral microbiome: diversity, biogeography and human health","volume":"22","author":"Baker","year":"2024","journal-title":"Nat. Rev. Microbiol"},{"key":"R28-91-20260310","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1136\/ard-2022-222549","article-title":"Lower disease activity but higher risk of severe COVID-19 and herpes zoster in patients with systemic lupus erythematosus with pre-existing autoantibodies neutralising IFN-\u03b1","volume":"81","author":"Mathian","year":"2022","journal-title":"Ann. Rheum. Dis"},{"key":"R29-91-20260310","doi-asserted-by":"crossref","DOI":"10.1016\/S2665-9913(25)00022-0","article-title":"Long-term effect of anifrolumab on patient-reported outcomes in systemic lupus erythematosus (TULIP-LTE): a randomised, placebo-controlled, phase 3 long-term extension trial","author":"Strand","year":"2025","journal-title":"Lancet Rheumatol"},{"issue":"Suppl. 1","key":"R30-91-20260310","doi-asserted-by":"crossref","first-page":"i55","DOI":"10.1093\/rheumatology\/kew427","article-title":"Pathways leading to an immunological disease: systemic lupus erythematosus","volume":"56","author":"Zharkova","year":"2017","journal-title":"Rheumatology"},{"key":"R31-91-20260310","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1136\/annrheumdis-2019-215089","article-title":"2019 update of the EULAR recommendations for the management of systemic lupus erythematosus","volume":"78","author":"Fanouriakis","year":"2019","journal-title":"Ann. Rheum. Dis"},{"key":"R32-91-20260310","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.jdcr.2023.04.024","article-title":"Successful treatment of severe chronic cutaneous lupus with anifrolumab: a series of 6 cases","volume":"37","author":"Kowalski","year":"2023","journal-title":"JAAD Case Rep"},{"key":"R33-91-20260310","article-title":"Revised Surgical CAse REport (SCARE) guideline: an update for the age of artificial intelligence","volume":"10","author":"Kerwan","year":"2025","journal-title":"Premier Journal of Science"}],"container-title":["International Journal of Surgery Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2210261225007795?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2210261225007795?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.ovid.com\/10.1016\/j.ijscr.2025.111593","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T18:31:10Z","timestamp":1786041070000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1016\/j.ijscr.2025.111593"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":33,"journal-issue":{"issue":"C","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1016\/j.ijscr.2025.111593","relation":{},"ISSN":["2210-2612"],"issn-type":[{"value":"2210-2612","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"2025-05-21","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-06-28","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}